Mustafa Özgüroğlu

Akademisyen

Alan: Tıp
Üniversite: İstanbul Üniversitesi-Cerrahpaşa
Fakülte ve Bölüm: Dahili Tıp Bilimleri Bölümü

Bu Sayfa Senin mi?

Sayfanı sahiplenirsen bilgilerini kendin güncelleyebilir, okurlardan mesaj alabilirsin.

Bir hata mı var?

Bu sayfa henüz sahiplenilmedi. İletişim bilgisi gösterilmiyor.

Bu sayfadaki bilgiler kamuya açık kaynaklardan derlendi.

Akademik Profiller

ORCID

Yayınlar

Tüm Yayınlar

1
Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II StudiesCancers
2022
2
1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361Journal of Clinical Oncology
2021
3
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial ExperienceThe Oncologist
2021
4
Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC)Journal of Clinical Oncology
2021
5
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJAMA Oncology
2021
6
Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC--an update from the PACIFIC trialJournal of Thoracic Oncology
2021
7
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trialThe Lancet
2021
8
Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLCJournal of Thoracic Oncology
2021
9
Durvalumab, with or without tremelimumab, plus platinum--etoposide versus platinum--etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology
2021
10
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology
2021

Yayın listesi ORCID kaydından alındı.